RT Journal Article
T1 Predictive Value of Immune Cell Functional Assay for Non-Cytomegalovirus Infection in Lung Transplant Recipients: A Multicenter Prospective Observational Study
A1 Monforte, Victor
A1 Ussetti, Piedad
A1 Castejon, Raquel
A1 Sintes, Helena
A1 Luz Perez, Virginia
A1 Laporta, Rosalia
A1 Sole, Amparo
A1 Manuel Cifrian, Jose
A1 Marcos, Pedro J.
A1 Redel, Javier
A1 Los Arcos, Ibai
A1 Berastegui, Cristina
A1 Alonso, Rodrigo
A1 Rosado, Silvia
A1 Escriva, Juan
A1 Iturbe, David
A1 Pablo Ovalle, Juan
A1 Manuel Vaquero, Jose
A1 Lopez-Meseguer, Manuel
A1 Mendoza, Alberto
A1 Gomez-Olles, Susana
K1 Immune cell assay
K1 Immunosuppression
K1 Infection
K1 Lung transplant
K1 Immunknow
K1 Adenosine-triphosphate production
K1 Recurrent hepatitis-c
K1 Cylex immuknow assay
K1 Working formulation
K1 Allograft-rejection
K1 Standardization
K1 Experience
K1 Risk
AB Introduction: Immune cell functional assay (ImmuKnow (R)) is a non-invasive method that measures the state of cellular immunity in immunosuppressed patients. We studied the prognostic value of the assay for predicting non-cytomegalovirus (CMV) infections in lung transplant recipients.Methods: A multicenter prospective observational study of 92 patients followed up from 6 to 12 months after transplantation was performed. Immune cell functional assay was carried out at 6, 8, 10, and 12 months.Results: Twenty-three patients (25%) developed 29 non-CMV infections between 6 and 12 months post-transplant. At 6 months, the immune response was moderate (ATP 225-525 ng/mL) in 14 (15.2%) patients and low (ATP = 525 ng/mL). Only 1 of 14 (7.1%) patients with a moderate response developed non-CMV infection in the following 6 months compared with 22 of 78 (28.2%) patients with low response, indicating sensitivity of 95.7%, specificity of 18.8%, positive predictive value (PPV) of 28.2%, and negative predictive value (NPV) of 92.9% (AUC 0.64; p = 0.043). Similar acute rejection rates were recorded in patients with mean ATP >= 225 vs. = 225 vs.
PB Elsevier espana slu
SN 0300-2896
YR 2021
FD 2021-11-01
LK https://hdl.handle.net/10668/25753
UL https://hdl.handle.net/10668/25753
LA en
DS RISalud
RD Apr 12, 2025